Literature DB >> 22761490

Primary correction of total anomalous pulmonary venous return with a modified sutureless technique.

Christoph Mueller1, Hitendu Dave, René Prêtre.   

Abstract

OBJECTIVES: The objective was to evaluate primary sutureless repair of total anomalous pulmonary venous return (TAPVR) in neonates using a modified technique that minimizes hypothermia and circulatory arrest times.
METHODS: From 2009 to 2011, seven consecutive patients underwent primary sutureless repair for the treatment of TAPVR, by which the prepared posterior pericardium was sutured to an opening in the left atrium. Three patients had the obstructed infracardiac type, and four patients had the unobstructed supracardiac type of TAPVR. Moderate hypothermia was used in all patients with a median temperature of 28°C (26-32). Circulatory arrest was not used except for the opening of the collector, which lasted between 3 and 5 min. The connecting vein was ligated in all seven patients (five during repair and two early postoperatively). The follow-up was 100% complete, with a median duration of 652 (range 370-1023) days.
RESULTS: There was no operative mortality and no late death. No patient required reoperation. Postoperative echocardiography showed unobstructed pulmonary venous flow in all patients. Recurrent pulmonary venous stenosis was not seen during the follow-up in any patient.
CONCLUSIONS: The sutureless technique is an effective technique with potential advantages even for the primary correction of TAPVR. With the described technique, the need for circulatory arrest is substantially reduced. Not handling the pulmonary venous collector by avoiding a direct anastomosis may contribute to better compliance, better growth and the absence of subsequent stenosis.

Entities:  

Mesh:

Year:  2012        PMID: 22761490     DOI: 10.1093/ejcts/ezs376

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Individual Pulmonary Veins Outgrow Somatic Growth After Primary Sutureless Repair for Total Anomalous Pulmonary Venous Drainage.

Authors:  Hyun-Jin Jung; Ji Hyun Bang; Chun-Soo Park; Jeong-Jun Park; Yu-Mi Im; Tae-Jin Yun
Journal:  Pediatr Cardiol       Date:  2015-10-03       Impact factor: 1.655

2.  Intrinsic obstruction in pulmonary venous drainage pathway is associated with poor surgical outcomes in patients with total anomalous pulmonary venous connection.

Authors:  Takaya Hoashi; Koji Kagisaki; Kenichi Kurosaki; Masataka Kitano; Isao Shiraishi; Hajime Ichikawa
Journal:  Pediatr Cardiol       Date:  2014-10-02       Impact factor: 1.655

3.  The Clinical Characteristics of 88 Patients with Total Anomalous Pulmonary Venous Connection and Risk Factors Associated with Early Postoperative Death.

Authors:  Lin Gui; An-Biao Wang; Jie Zi; Ge-Yi Ai; Hui-Hui Wang; Mei Zhu; Hao Liang
Journal:  Int J Gen Med       Date:  2022-10-13

4.  Midterm outcomes of sutureless technique for postoperative pulmonary venous stenosis.

Authors:  Kizuku Yamashita; Takaya Hoashi; Koji Kagisaki; Kenichi Kurosaki; Isao Shiraishi; Toshikatsu Yagihara; Hajime Ichikawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-08-06

5.  Comparison of conventional and primary sutureless surgery for repairing supracardiac total anomalous pulmonary venous drainage.

Authors:  Yongfeng Zhu; Hewen Qi; Yunzhou Jin
Journal:  J Cardiothorac Surg       Date:  2019-02-08       Impact factor: 1.637

6.  Sutureless Technique for Primary Total Anomalous Pulmonary Venous Connection Repair: An Updated Meta-Analysis.

Authors:  Lu Zhao; Zhengxia Pan; Chun Wu; Lianju Shen; Yuhao Wu
Journal:  Front Cardiovasc Med       Date:  2022-04-28

Review 7.  Sutureless technique versus conventional surgery in the primary treatment of total anomalous pulmonary venous connection: a systematic review and meta-analysis.

Authors:  Yuhao Wu; Zhichao Wu; Junmeng Zheng; Yonggang Li; Yuehang Zhou; Hongyu Kuang; Xin Jin; Chun Wu
Journal:  J Cardiothorac Surg       Date:  2018-06-15       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.